Transnasal Versus Suprazygomatic SPG Block in Persistant Idiopathic Facial Pain

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

April 1, 2023

Study Completion Date

April 2, 2023

Conditions
HeadachePersistent Idiopathic Facial Pain
Interventions
DRUG

Transnasal Sphenopalatine ganglion block

The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.

DRUG

Ultrasound-guided suprazygomatic sphenopalatine ganglion block

The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.

Trial Locations (1)

06100

Ankara Etlik City Hospital, Ankara

All Listed Sponsors
lead

Diskapi Teaching and Research Hospital

OTHER